Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-27

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will determine whether a range of products along the reduced-risk continuum can reduce smoke exposure for individuals who fail to quit smoking using current medically approved nicotine replacement therapy (NRT) products. The strategy will be to offer 325 smokers four weeks of NRT of their choice (gum, lozenge, or nicotine patch) and assess them for quit-smoking status at the end of the period. Seven-day point abstinence will be used to determine responder status at the end of the four-week period (CO of \<6 ppm at both CO collection points during that seven-day period and self-report of no smoking during that seven-day period). Those who have not quit, and who therefore have a very low chance of later success (a consistent finding in prior studies and to be verified in the proposed study), will be randomly assigned to either receive a potential "rescue" product (nicotine pouch or ENDS (electronic nicotine delivery system), or remain on NRT (control group).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders

NCT06554873

Smoking Cessation Harm Reduction

COMPLETED PHASE3

Effectiveness of Different THR Products in Adult Population

NCT05825924

Smoking Cessation

NOT_YET_RECRUITING PHASE3

Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype

NCT00894166

Smoking Cessation

COMPLETED PHASE3

e-Cigarettes Versus NRT Gum for Smoking Cessation

NCT01925781

Nicotine Addiction Smoking Cessation

TERMINATED PHASE4

Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction

NCT04210180

Smoking Cessation Harm Reduction

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking Cessation Harm Reduction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I - NRT Responder

Participants that were successful in quitting smoking using NRT in the first four weeks of the study will have the option of remaining on their current NRT or switching to one of the other two options for the next five weeks.

Group Type EXPERIMENTAL

Nicoderm

Intervention Type DRUG

21mg nicotine patch daily; maximum usage 9 weeks

Nicorette 4Mg Chewing Gum

Intervention Type DRUG

4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks

Nicorette Lozenge Product

Intervention Type DRUG

4mg Nicorette mint lozenge; as needed maximum usage 9 weeks

Group IIa NRT Non-Responder - Pouch Preferrers

Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try a nicotine pouch. Randomized to be switched to nicotine pouch for the next five weeks.

Group Type EXPERIMENTAL

Nicoderm

Intervention Type DRUG

21mg nicotine patch daily; maximum usage 9 weeks

Nicorette 4Mg Chewing Gum

Intervention Type DRUG

4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks

Nicorette Lozenge Product

Intervention Type DRUG

4mg Nicorette mint lozenge; as needed maximum usage 9 weeks

on!

Intervention Type OTHER

4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 5 weeks

Group IIb NRT Non-Responder - Pouch Preferrers Control

Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try a nicotine pouch. Randomized to be remain on NRT for the next five weeks.

Group Type EXPERIMENTAL

Nicoderm

Intervention Type DRUG

21mg nicotine patch daily; maximum usage 9 weeks

Nicorette 4Mg Chewing Gum

Intervention Type DRUG

4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks

Nicorette Lozenge Product

Intervention Type DRUG

4mg Nicorette mint lozenge; as needed maximum usage 9 weeks

Group IIIa NRT Non-Responder - ENDS Preferrers

Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try ENDS. Randomized to be switched to ENDS for the next five weeks.

Group Type EXPERIMENTAL

Nicoderm

Intervention Type DRUG

21mg nicotine patch daily; maximum usage 9 weeks

Nicorette 4Mg Chewing Gum

Intervention Type DRUG

4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks

Nicorette Lozenge Product

Intervention Type DRUG

4mg Nicorette mint lozenge; as needed maximum usage 9 weeks

BIDI e-cigarette

Intervention Type OTHER

BIDI e-cigarette (flavors - Classic, Arctic, and Solar); as needed for maximum of 5 weeks

Group IIIb NRT Non-Responder - ENDS Preferrers Control

Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try ENDS. Randomized to be remain on NRT for the next five weeks.

Group Type EXPERIMENTAL

Nicoderm

Intervention Type DRUG

21mg nicotine patch daily; maximum usage 9 weeks

Nicorette 4Mg Chewing Gum

Intervention Type DRUG

4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks

Nicorette Lozenge Product

Intervention Type DRUG

4mg Nicorette mint lozenge; as needed maximum usage 9 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nicoderm

21mg nicotine patch daily; maximum usage 9 weeks

Intervention Type DRUG

Nicorette 4Mg Chewing Gum

4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks

Intervention Type DRUG

Nicorette Lozenge Product

4mg Nicorette mint lozenge; as needed maximum usage 9 weeks

Intervention Type DRUG

BIDI e-cigarette

BIDI e-cigarette (flavors - Classic, Arctic, and Solar); as needed for maximum of 5 weeks

Intervention Type OTHER

on!

4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 5 weeks

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nicotine Patch Nicotine gum Nicotine lozenge Nicotine pouch

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has signed the Informed Consent From (ICF) and is able to read and understand the information provided in the ICF.
2. Is 22 to 65 years of age (inclusive) at screening.
3. Smokes an average of at least 10 commercially available cigarettes per day and has done so for the last 12 months.
4. Expired air CO reading of at least 10 ppm as assessed at the screening session.
5. Interested in switching to an electronic cigarette or nicotine pouch.
6. Willing and able to comply with the requirements of the study.
7. Owns a smart phone with text message and data capabilities compatible with necessary surveys.

Exclusion Criteria

1. Any participant who has a medical or physical condition that, in the opinion of the investigator (or designee), may adversely affect participant safety, the safety of others, or data validity.
2. Planned use of an FDA-approved smoking cessation product during the study, not provided as part of this protocol.
3. Coronary heart disease, structural cardiac disease (including, but not limited to valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac chest pain, or history of heart attack or heart failure.
4. Taking psychoactive medications (e.g., antipsychotics, benzodiazepines, or mood stabilizers).
5. Frequent users (monthly) of smokeless tobacco (chewing tobacco, snuff), cigars (not cigarillos), pipes, hookahs or other non-commercially available combustible or heated tobacco products.
6. Use of nicotine replacement therapy or other smoking cessation treatments within 14 days of screening.
7. Pregnant or nursing (by self-report) or positive pregnancy test.
8. Heterosexually active participant of Childbearing Potential (not sterilized by tubal ligation, oophorectomy, hysterectomy, or other surgical methods, or post-menopausal) that do not agree to practice medically appropriate methods of birth control (or remain abstinent) during the course of the trial. Medically acceptable methods of birth control include: successful vasectomy of male partner, vaginal diaphragm with spermicide, intrauterine device, hormonal birth control (oral, injected, or implanted), condom with spermicide, or sponge with spermicide.
9. Participants who were enrolled in a clinical trial within 30 days of screening.
10. Enrollment numbers met (in sub-group or entire study).

Minimum Eligible Age

22 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes